TY - JOUR
T1 - Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020
AU - European Cystic Fibrosis COVID project group
AU - Naehrlich, Lutz
AU - Orenti, Annalisa
AU - Dunlevy, Fiona
AU - Kasmi, Irena
AU - Harutyunyan, Satenik
AU - Pfleger, Andreas
AU - Keegan, Svetlana
AU - Daneau, Géraldine
AU - Petrova, Guergana
AU - Tješić-Drinković, Duška
AU - Yiallouros, Panayiotis
AU - Bilkova, Alena
AU - Olesen, Hanne Vebert
AU - Burgel, Pierre Régis
AU - Parulava, Tsitsino
AU - Diamantea, Filia
AU - Párniczky, Andrea
AU - McKone, Edward F.
AU - Mei-Zahav, Meir
AU - Salvatore, Marco
AU - Colombo, Carla
AU - Aleksejeva, Elina
AU - Malakauskas, Kestutis
AU - Schlesser, Marc
AU - Fustik, Stojka
AU - Turcu, Oxana
AU - Zomer-van Ommen, Domenique
AU - Wathne, Anita Senstad
AU - Woźniacki, Łukasz
AU - Pereira, Luísa
AU - Pop, Liviu
AU - Kashirskaya, Nataliya
AU - Rodić, Milan
AU - Kayserova, Hana
AU - Krivecs, Uro
AU - Mondejar-Lopez, Pedro
AU - de Monestrol, Isabelle
AU - Dogru, Deniz
AU - Makukh, Halyna
AU - Cosgriff, Rebecca
AU - van Koningsbruggen-Rietschel, Silke
AU - Jung, Andreas
AU - Bobrovnichy, Vladimir
AU - Bambir, Ivan
AU - Vukic, Andrea Dugac
AU - Drevinek, Pavel
AU - Jr, Milan Macek
AU - Corvol, Harriet
AU - Lemonnier-Videau, Lydie
AU - Hatziagorou, Elpis
N1 - Publisher Copyright:
© 2021
PY - 2021/7
Y1 - 2021/7
N2 - Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.
AB - Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.
KW - Covid-19
KW - Cystic fibrosis
KW - Epidemiology
KW - Europe
KW - Incidence
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85110442858&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2021.03.017
DO - 10.1016/j.jcf.2021.03.017
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34016559
AN - SCOPUS:85110442858
SN - 1569-1993
VL - 20
SP - 566
EP - 577
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 4
ER -